| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_chr20_0166300 | Intergenic-Intergenic | chr20:42333985-42343915 | chr20:43705345-43715275 | 475 nt | 0.5705 |
| hsa_MYBL2_0003600 | Exon-Exon | chr20:42338603-42340170 | chr20:43709963-43711530 | 143 nt | 0.5944 |
| hsa_chr20_0166400 | Intergenic-Intergenic | chr20:42338899-42339372 | chr20:43710259-43710732 | 474 nt | 0.5338 |
| hsa_MYBL2_0003700 | Intron-Intron | chr20:42338976-42339119 | chr20:43710336-43710479 | 144 nt | 0.4792 |
A study in human acute myeloid leukemia (AML) demonstrated that the circMYBL2 is crucial for FLT3-dependent leukemia progression, where it interacts with PTBP1 to increase mutant FLT3 kinase protein levels [Di Agostino et al. DOI:10.3389/fcell.2020.00389]. A study in humans demonstrated that the circMYBL2 is a circular RNA with expression restricted to venous blood samples, serving as a specific biomarker for body fluid identification [Yu et al. DOI:10.1016/j.fsigen.2025.103416].